Cardiovascular and renal safety outcomes of hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat for anemia patients with chronic kidney disease: a systematic review and meta-analysis
This systematic review and meta-analysis were conducted to evaluate the cardiac and kidney-related adverse effects of roxadustat for the treatment of anemia in CKD patients. 18 trials with a total of 8806 participants were identified for analysis. We employed a fixed-effects model for analysis. The...
Saved in:
Main Authors: | Lei Tian, Mengdi Wang, Mengchao Liu, Yanyu Pang, Jingwen Zhao, Bingjie Zheng, Yutong Wang, Wenjing Zhao |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2024-12-01
|
Series: | Renal Failure |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/0886022X.2024.2313864 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Influencing factors of clinical efficacy of roxadustat among hemodialysis patients
by: Wenhui Wu, et al.
Published: (2024-12-01) -
Mitophagy mediated by HIF-1α/FUNDC1 signaling in tubular cells protects against renal ischemia/reperfusion injury
by: Wenjun Zhang, et al.
Published: (2024-12-01) -
Decrease in platelet count in patients with AKI and its association with major adverse kidney events
by: Ramón Medina-González, et al.
Published: (2024-12-01) -
EEG as a neural measure of hypoxia-related impairment
by: Stephanie R. Otto, et al.
Published: (2025-02-01) -
Clinical advances in kidney autotransplantation: a review
by: Shengjie Lin, et al.
Published: (2025-02-01)